摘要
中药活性成分广泛存在水溶性低、稳定性差等问题,这在一定程度上限制了其成药性和临床应用。共晶技术作为一种常用的晶体工程策略,在改善中药活性成分的理化性质及提升其成药性方面展现出了巨大潜力。综述系统介绍了中药活性成分共晶的开发与应用进展,探讨共晶在改善中药活性成分成药性方面的潜力及局限性,以期为中药活性成分的共晶技术研究与新药开发提供参考。
The active components of traditional Chinese medicine(TCM)often exhibit low water solubility and poor stability,which results in poor druggability and limited clinical application.As a commonly used crystal engineering strategy,co-crystallization shows great potential in improving the physicochemical properties of TCM and enhancing their druggability.This review gives a comprehensive introduction to the development and application of pharmaceutical cocrystals in TCM and explores the potential and limitations of cocrystallization in improving the druggability of TCM active components,aiming to provide useful information for co-crystallization research and drug development of TCM.
作者
李泽宇
申欢
刘二刚
蒙钰珏
黄永焯
LI Zeyu;SHEN Huan;LIU Ergang;MENG Yujue;HUANG Yongzhuo(School of Pharmaceutical Sciences,Guangzhou University of Chinese Medicine,Guangzhou 510006,China;Zhongshan Institute for Drug Discovery,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Zhongshan 528400,China;State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China)
出处
《药学进展》
CAS
2024年第10期770-781,共12页
Progress in Pharmaceutical Sciences
基金
国家重点研发计划(No.2021YFC2400603,No.2021YFE0103100,No.2022YFE0203600)
国家自然科学基金(No.81925035,No.82341232)
中山市引进科研创新领军人才项目和岭南药物研究创新团队(No.LJ2021001,No.CXTD2022011)
2023年度中山市第二批社会公益与基础研究项目(No.2023B2033)
广东省科技厅高水平创新研究机构项目(No.2021B0909050003)。
关键词
中药活性成分
药物共晶
成药性
中药新药研究
active components of traditional Chinese medicine
pharmaceutical cocrystal
druggability
development of novel Chinese medicine
